Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer

The PI3K/AKT pathway is frequently altered in advanced human prostate cancer mainly through the loss of functional PTEN, and presents as potential target for personalized therapy. Our aim was to determine the therapeutic potential of the pan-AKT inhibitor, AZD5363, in PTEN-deficient prostate cancer....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: De Velasco, Marco A., Kura, Yurie, Yoshikawa, Kazuhiro, Nishio, Kazuto, Davies, Barry R., Uemura, Hirotsugu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2016
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4941290/
https://ncbi.nlm.nih.gov/pubmed/26910118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7557
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg